Optimal Clinical Assessment Strategies for Chemotherapy-induced Peripheral Neuropathy (CIPN): a Systematic Review and Delphi Survey

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2017 Jun 8

PMID 28589310

Citations 44

Authors

J Matt McCrary

David Goldstein

Frances Boyle

Keith Cox

Peter Grimison

Matthew C Kiernan

Arun V Krishnan

Craig R Lewis

Kate Webber

Sally Baron-Hay

Lisa Horvath

Susanna B Park

Affiliations

Soon will be listed here.

Abstract

Background/purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a prominent side effect of the treatment of cancer. Despite this frequent complication, there has been no comprehensive review and quality appraisal of CIPN assessments. The purpose of this study is to provide a definitive quality appraisal of CIPN assessment strategies for clinical use.

Methods: Relevant studies were identified through database searches of Medline, Embase, CINAHL, and Cochrane. CIPN assessment strategies from included articles were extracted and initially rated by an oncologist and neurophysiologist according to criteria related to assessment depth, comprehensiveness, appropriateness, and reliability. The six highest scoring assessment strategies were the focus of a two-round Delphi survey of a working party of 32 physicians, nurses, and consumers to achieve consensus on the highest rated assessments for each criterion.

Results: The database search yielded 117 distinct CIPN assessments that were extracted from 2373 articles. Three patient-reported outcome surveys and three clinician-based assessments were included in the Delphi survey. No consensus was generated regarding the best overall CIPN assessment, although good (≥70%) consensus was achieved regarding the best assessment within each criterion. The Participant Neurotoxicity Questionnaire (PNQ) was rated the highest overall and patient-reported outcome (PRO) assessment, while the Total Neuropathy Score clinical version (TNSc) was the highest rated clinician-based assessment.

Conclusions: A diverse range of CIPN assessments currently exists. While several assessments assess CIPN symptoms with adequate comprehensiveness, depth, language, and feasibility, the consensus 'gold standard' clinical assessment remains to be established.

Citing Articles

Kruse F, Bille M, Lendorf M, Vaabengaard S, Birk S Acta Oncol. 2025; 64():78-86.

PMID: 39815403 PMC: 11748177. DOI: 10.2340/1651-226X.2025.42109.

Chemotherapy-induced peripheral neuropathy and its determinants among adult cancer patients on chemotherapy in northwest Ethiopia oncology centers, 2022.

Habtie T, Abate M, Abebe G, Wolie Z, Alamaw A, Mitiku H Front Oncol. 2024; 14:1420518.

PMID: 39720571 PMC: 11666479. DOI: 10.3389/fonc.2024.1420518.

Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.

Li T, Timmins H, Mahfouz F, Trinh T, Mizrahi D, Horvath L JAMA Netw Open. 2024; 7(8):e2424139.

PMID: 39120903 PMC: 11316238. DOI: 10.1001/jamanetworkopen.2024.24139.

Centralizing the Knowledge and Interpretation of Pain in Chemotherapy-Induced Peripheral Neuropathy: A Paradigm Shift towards Brain-Centric Approaches.

Cunha M, Tavares I, Costa-Pereira J Brain Sci. 2024; 14(7).

PMID: 39061400 PMC: 11274822. DOI: 10.3390/brainsci14070659.

Chemotherapy-Induced Peripheral Neuropathy: Assessment and Treatment Strategies for Advanced Practice Providers.

Preti K, Davis M Clin J Oncol Nurs. 2024; 28(4):351-357.

PMID: 39041696 PMC: 11674975. DOI: 10.1188/24.CJON.351-357.

References

Gewandter J, Burke L, Cavaletti G, Dworkin R, Gibbons C, Gover T . Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. Muscle Nerve. 2016; 55(3):366-372. PMC: 5528159. DOI: 10.1002/mus.25264. View

Cornblath D, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M . Total neuropathy score: validation and reliability study. Neurology. 1999; 53(8):1660-4. DOI: 10.1212/wnl.53.8.1660. View

Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C . Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008; 44(11):1507-15. DOI: 10.1016/j.ejca.2008.04.018. View

Postma T, Heimans J . Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2000; 11(5):509-13. DOI: 10.1023/a:1008345613594. View

Lauria G, Hsieh S, Johansson O, Kennedy W, Leger J, Mellgren S . European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the.... Eur J Neurol. 2010; 17(7):903-12, e44-9. DOI: 10.1111/j.1468-1331.2010.03023.x. View

England J, Gronseth G, Franklin G, Miller R, Asbury A, Carter G . Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005; 64(2):199-207. DOI: 10.1212/01.WNL.0000149522.32823.EA. View

Kolb N, Smith A, Singleton J, Beck S, Stoddard G, Brown S . The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol. 2016; 73(7):860-6. PMC: 6715416. DOI: 10.1001/jamaneurol.2016.0383. View

Hershman D, Weimer L, Wang A, Kranwinkel G, Brafman L, Fuentes D . Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2010; 125(3):767-74. DOI: 10.1007/s10549-010-1278-0. View

Griffith K, Merkies I, Hill E, Cornblath D . Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst. 2011; 15(4):314-25. DOI: 10.1111/j.1529-8027.2010.00292.x. View

10.

Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C . The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007; 12(3):210-5. DOI: 10.1111/j.1529-8027.2007.00141.x. View

11.

Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C . Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006; 11(2):135-41. DOI: 10.1111/j.1085-9489.2006.00078.x. View

12.

Kroigard T, Schroder H, Qvortrup C, Eckhoff L, Pfeiffer P, Gaist D . Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol. 2014; 21(4):623-9. DOI: 10.1111/ene.12353. View

13.

Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P . Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010; 46(3):479-94. DOI: 10.1016/j.ejca.2009.12.008. View

14.

Smith E, Barton D, Qin R, Steen P, Aaronson N, Loprinzi C . Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res. 2013; 22(10):2787-99. PMC: 4383166. DOI: 10.1007/s11136-013-0379-8. View

15.

Boonen A, van Berkel M, Kirchberger I, Cieza A, Stucki G, van der Heijde D . Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. Rheumatology (Oxford). 2009; 48(8):997-1002. DOI: 10.1093/rheumatology/kep150. View

16.

Griffith K, Couture D, Zhu S, Pandya N, Johantgen M, Cavaletti G . Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer. 2013; 22(5):1161-9. PMC: 3969764. DOI: 10.1007/s00520-013-2068-0. View

17.

Di Maio M, Gallo C, Leighl N, Piccirillo M, Daniele G, Nuzzo F . Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015; 33(8):910-5. DOI: 10.1200/JCO.2014.57.9334. View

18.

Tofthagen C, McMillan S, Kip K . Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs. 2011; 34(4):E10-20. DOI: 10.1097/NCC.0b013e31820251de. View

19.

Hovaguimian A, Gibbons C . Diagnosis and treatment of pain in small-fiber neuropathy. Curr Pain Headache Rep. 2011; 15(3):193-200. PMC: 3086960. DOI: 10.1007/s11916-011-0181-7. View

20.

Park S, Goldstein D, Krishnan A, Lin C, Friedlander M, Cassidy J . Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2014; 63(6):419-37. DOI: 10.3322/caac.21204. View